IN BRIEF: Oxford Biomedica confirms fresh EQT takeover approach

Related news

Oxford BioMedica PLC - Oxford, England-based gene and cell therapy developer - Says it notes recent press speculation and that it has received an unsolicited approach, regarding a possible cash takeover offer, from EQT X EUR SCSp and EQT X USD SCSp, funds managed by EQT Fund Management Sarl. Says it and EQT are in preliminary discussions to explore whether EQT could make a proposal which OXB’s board would want to recommend. Previous unsolicited proposals from EQT have been rejected, as OXB’s board believed they undervalued it and its prospects. Company ‘strongly’ advises shareholders to take no action at this time.

Current stock price: 748.71 pence, up 1.3% on Wednesday in London

12-month change: up 91%

Copyright 2026 Alliance News Ltd. All Rights Reserved.

Bids, mergers and takeovers

Ways to help you invest your money

Our investment accounts

Put your money to work with our range of investment accounts. Choose from ISAs, pensions, and more.

Need some investment ideas?

Let us give you a hand choosing investments. From managed funds to favourite picks, we’re here to help.

Read our expert tips and insights

Our investment experts share their knowledge on how to keep your money working hard across the markets.